Navigation Links
Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe

BETHLEHEM, Pa., Dec. 16, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, today announced it has entered into distribution agreements with Genoxa of Puck, Poland and AB ANALITICA of Padua, Italy, for My5-FU™, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients. 

"Our new partnership with AB ANALITICA and Genoxa continues the expansion of our marketing and distribution channels in Europe, which will facilitate adoption of 5-FU dose management in these new markets for Saladax," said Adrienne Choma, Esq., senior vice president and Chief Marketing Officer of Saladax.

Genoxa will be the exclusive provider of My5-FU testing services to oncologists in Poland, enabling them to individualize the dose of 5-FU to optimize therapeutic efficacy and reduce toxicity for their patients.  Genoxa is a privately owned clinical reference laboratory focused on providing personalized medicine testing services.  "We are pleased to introduce this exciting new technology from Saladax to the Polish oncology community and offer cancer patients better treatment options," commented Artur Wilandt, co-founder and CEO of Genoxa.

In Italy, AB ANALITICA will be the exclusive distributor of My5-FU testing kits to hospital and reference laboratories.  Mikkel Johansen, marketing manager for AB ANALITICA, said, "We are delighted with our partnership with Saladax.  The addition of My5-FU fits nicely into our current portfolio of diagnostic tests."  AB ANALITICA is focused on the development and commercialization of diagnostic tests for human infectious diseases, oncology, genetic diseases, target therapies and pharmacogenetics. 

About My5-FU
Saladax's first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.

About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems.  In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit, or follow us on Twitter at

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Senior VP & Chief Marketing Officer

Media Contact:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
Jason Rando

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Companys Scientific Advisory Board
2. Saladax Biomedical, Inc. Enters Agreement with Kaan Medikal for Distribution of My5-FU in Turkey
3. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
4. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
5. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
6. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
7. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
8. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
9. Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools
10. Sony Expands Radiology Product Offerings with Full Line of Diagnostic Displays
11. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
Post Your Comments:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):